Tochi M. Okwuosa, DO, Rush University Medical Center, discusses ways in which cancer treatments can adversely affect heart health outcomes for patients under the care of oncologists.
Tochi M. Okwuosa, DO, cardiologist and director of cardio-oncology at Rush University Medical Center in Chicago, discusses how physical health and treatment for cancer interact, often resulting in adverse heart health outcomes for patients under the care of oncologists.
Transcript
What risk factors predispose cancer survivors to a higher risk of cardiac disease/damage?
Certain sorts of the typical cardiovascular risk factors, their comorbid conditions, if they have lung disease, kidney disease—all of that affects the patient. The kinds of cancer treatments that particularly affect the patient, the prototypical one is anthracyclines. Those are the sorts of treatments that are used for breast cancer, for lymphoma, for some of the leukemias; some of the GI [gastrointestinal] cancers use them. Anthracyclines are the particular ones that are known to cause heart failure and cardiac toxicity. But there's a whole lot of other ones.
Trastuzumab, or Herceptin, type of treatments, anti-HER2 [human epidermal growth factor receptor 2] therapy that are used for treatment of breast cancer. Then there's tyrosine kinase inhibitors that are used for practically all the different kinds of cancers, in one shape or form, that have cardiovascular consequences like heart failure and hypertension and so on. There's Bruton kinase inhibitors like ibrutinib and acalabrutinib, that increase the risk of arrhythmias. There is 5-FU, or 5-fluorouracil, and capecitabine, that increase the risk of coronary spasms and heart attacks as a result.
There's radiation therapy that increases the risk of valvular heart disease, coronary artery disease, arrhythmias, pericardial diseases. And then there's more recent, more modern-day therapies like immunotherapies that can increase the risk of myocarditis, or inflammation of the heart muscle, and there is the CAR [chimeric antigen receptor] T-cell therapy, which is also a type of immunotherapy, that can cause what we call CRS, or cytokine release syndrome, that can have consequences on the heart and cause cardiovascular collapse and hypotension, which can lead to death. And stem cell transplant, which has long-term consequences, because it's not just the chemotherapy that they receive prior to stem cell and during stem cell, it's also a function of the immunosuppressive therapy that some of them have to be on for a long time that can affect the heart.
Practically all the different forms of cancer have some sort of therapy or therapies that have cardiovascular consequences that we have to think about. And that's on top of the comorbid conditions and the cardiovascular risk factors and the social determinants of health and all these other things that can influence outcomes in patients.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More